ORION: Durvalumab plus Olaparib Versus Durvalumab Alone as Maintenance Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Ahn, M. [1 ]
Liu, Y. [2 ]
Improta, T. [3 ]
Marcovitz, M. [2 ]
Dipiazza, K. [2 ]
Lanasa, M. [2 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[2] Astrazeneca, Gaithersburg, MD USA
[3] Astrazeneca, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
D O I：
10.1016/j.jtho.2019.08.1362
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-18
引用
收藏
页码：S645 / S646
页数：2
相关论文
共 50 条
  • [1] ORION: A Phase 2, randomized, multicenter, doubleblind study to assess efficacy and safety of durvalumab plus olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).
    Ahn, Myung-Ju
    Liu, Yufan
    Improta, Teresa
    Marcovitz, Michelle
    DiPiazza, Kate
    Lanasa, Mark C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study
    Ahn, Myung-Ju
    Bondarenko, Igor
    Kalinka, Ewa
    Cho, Byoung Chul
    Sugawara, Shunichi
    Galffy, Gabriella
    Shim, Byoung Yong
    Kislov, Nikolay
    Nagarkar, Rajnish
    Demedts, Ingel
    Gans, Steven J. M.
    Oliva, Dolores Mendoza
    Stewart, Ross
    Lai, Zhongwu
    Mann, Helen
    Shi, Xiaojin
    Hussein, Maen
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : 1594 - 1606
  • [3] Durvalumab plus Olaparib vs Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: Outcomes from the Phase 2 ORION Study
    Ahn, M-J.
    Spigel, D.
    Bondarenko, I.
    Kalinka, E.
    Cho, B. C.
    Sugawara, S.
    Galffy, G.
    Shim, B. Y.
    Kislov, N.
    Nagarkar, R.
    Demedts, I.
    Gans, S. J. M.
    Oliva, D. M.
    Stewart, R.
    Lai, Z.
    Grainger, E.
    Shi, X.
    Hussein, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S124 - S125
  • [4] Durvalumab (D) in combination with olaparib (O) for advanced, previously treated non-small cell lung cancer (NSCLC).
    Desmond, Daniel
    Vilimas, Rasa
    Mullenix, Cristina
    Zhao, Chen
    Szabo, Eva
    Shelat, Meenakshi
    Ballman, Madison
    Sansone, Susan
    Steinberg, Seth M.
    Lee, Jung-Min
    Rajan, Arun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer: CRUISER study
    Teng, Feifei
    Ge, Hong
    Wang, Buhai
    Xu, Yaping
    Meng, Xue
    Wang, Suzhen
    Xing, Ligang
    Yu, Jinming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Durvalumab for the treatment of non-small cell lung cancer
    Mezquita, Laura
    Planchard, David
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (08) : 627 - 639
  • [7] Durvalumab for the treatment of non-small cell lung cancer
    Murakami, Shuji
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (12) : 1009 - 1016
  • [8] Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
    Tomasini, Pascale
    Greillier, Laurent
    Boyer, Arnaud
    Jeanson, Arnaud
    Barlesi, Fabrice
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1032 - S1036
  • [9] Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
    Duma, Narjust
    Mansfield, Aaron S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S89 - S93
  • [10] COST-EFFECTIVENESS OF DURVALUMAB AFTER CHEMORADIATION IN STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)
    Criss, S. D.
    Mooradian, M. J.
    Lumish, M. A.
    Reynolds, K. L.
    Kong, C. Y.
    VALUE IN HEALTH, 2018, 21 : S12 - S12
12345